Liver transplantation (LT) offers the best chance of survival in selected patients with hepatocellular carcinoma (HCC). Wait-list mortality or dropout due to tumor progression can be significant, and therefore, timely transplantation is critical. Liver grafts discarded by outside organ procurement organizations are a potential source of grafts for low Model for EndStage Liver Disease tumor patients. The primary aim of this study was to assess the disease-free and overall survival of patients with HCC transplanted with imported liver grafts (ILGs). Review of all patients transplanted for HCC between June 2005 and December 2014 was performed. Data on demographics, survival, and HCC recurrence were analyzed. During this time period, 59 out of 190 (31%) recipients with HCC received ILG. Of these 59 grafts, 54 were imported from within the region and 5 were from national offers (outside the region). The mean cold ischemia time for local liver grafts (LLGs) was 4.1 6 1.5 hours versus 5.1 6 1.4 hours for ILG (P < 0.001). The 1-, 3-, and 5-year patient survival was 90%, 85%, and 83% and 85%, 80%, and 79% for LLG and ILG (P 5 0.08), respectively. The observed disease recurrence rate for both LLG and ILG recipients was equivalent. The median wait-list time for HCC recipients was 43 days (range, 2-1167 days). In conclusion, with careful graft assessment, the use of ILGs results in comparable outcomes following LT and no increased risk of HCC recurrence. Use of ILGs maximizes the donor pool and results in a higher rate of transplantation for HCC recipients.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death in the United States. Liver transplantation (LT) offers the best treatment for selected patients with HCC and chronic liver disease. (1, 2) In the post-Model for End-Stage Liver Disease (MELD) era, transplant centers are faced with the challenge of an increasing proportion of HCC patients populating the waiting list. Furthermore, with improved longterm cancer-free outcomes, several centers are carefully expanding the use of LT as the treatment of choice for HCC even beyond the Milan criteria. (3) (4) (5) The demand for deceased organs has steadily exceeded the static supply in the available donor pool. Longer wait times to transplantation for patients with HCC leads to increased wait-list mortality and/or dropout due to tumor progression. One strategy to expand the donor pool is to use liver grafts that are classified as "marginal" or from extended criteria donors (ECDs). (6) In the United States, once such grafts are declined by all centers within the local donor organ procurement organization (OPO), they are allocated regionally first (as defined by the current United Network for Organ Sharing [UNOS] regions map) by descending MELD score and then nationally. Many of these imported liver grafts (ILGs) have a perceived risk of impaired graft function or increased risk of donor-transmitted diseases. Furthermore, because these grafts travel from farther distances, cold ischemia times (CITs) are lengthened. Because of the increased CIT and ECD graft status, it has been hypothesized that these organs likely have a heightened ischemia/ reperfusion injury (IRI). This is thought to result in an enhanced growth factor release that could potentially stimulate tumor cell growth and/or metastasis making these less than ideal liver grafts for HCC recipients. (7) Acceptable outcomes using ECD liver grafts for transplantation has been demonstrated by other centers. However, their use in HCC recipients is not well documented. (8, 9) The primary aim of this study is to present a single center's experience with ILGs for HCC recipients and assess for any potential increased risk of HCC recurrence in these patients.
Patients and Methods
A retrospective analysis of all organ offers for HCC recipients between June 2005 and December 2014 was performed. All patients with tumors beyond Milan criteria (a single tumor up to 5 cm or 3 tumors none greater than 3 cm) underwent pretransplant downstaging with radiofrequency ablation or chemoembolization. Successful downstaging was defined as tumor shrinkage to within Milan criteria or absence of viable tumor on follow-up imaging and maintenance within Milan criteria for 3 months prior to listing (in accordance with region 3 policy). All offers inside and outside the local OPO were carefully assessed for quality. The gross and microscopic appearance of each liver graft was evaluated using photographic documentation and hematoxylineosin staining of the liver biopsy specimen. Frozen sections were assessed for relevant microscopic features (ie, steatosis, inflammation, and fibrosis) by a pathologist at the donor hospital and by our liver pathology and surgery teams. The risks and benefits of LT with ILG were fully discussed with the recipients, and appropriate consent was obtained prior to surgery. All patients listed for transplant are candidates to receive ILG. Patients listed with a diagnosis of HCC have tumors within Milan criteria either on presentation or were downstaged to within criteria. ILGs are treated in a similar fashion to a local liver graft (LLG) being offered to patients with the highest MELD score first (based on the local center list) with the caveat that the recipients are considered ideal patients for ILGs. Ideal candidates have no history of prior major upper abdominal surgery, no known portal vein thrombosis, and a low natural MELD. The goal when transplanting ILG is to keep the CIT short and have the implantation in a favorable environment (ie, low transfusion and pressor requirements). Therefore, recipients that are deemed to have conditions for a favorable hepatectomy are selected. For patients who received donation after cardiac death (DCD) grafts, an institutional DCD protocol was followed which included the use of intraoperative thrombolytics (ie, tissue plasminogen activator), and recipients were placed postoperatively on entericcoated aspirin (325 mg daily). (10) The compiled demographic, pathologic, and clinical variables included sex, age, waiting time, physiological MELD score, cold and warm ischemia times, and graft steatosis. The donor risk index (DRI) was also calculated for all grafts. (11) The measured outcome variables included liver graft complications, acute kidney injury, length of hospital stay, tumor histopathology, survival, and tumor recurrence. Technical complications were categorized into biliary and vascular. Hepatic artery thrombosis (HAT) was defined as "early" when thrombosis occurred within the first 21 days after transplantation. Biliary complications diagnosed subsequent to the diagnosis of HAT were not treated as independent events. Biliary tract complications were classified as either a leak or stricture. Primary nonfunction was defined as graft failure leading to retransplantation or death within 7 days after LT. (12) Acute kidney injury was defined as an increase in serum creatinine to 1.5 times baseline occurring within 7 days after transplant. (13) Explant pathology was classified by a liver histopathologist and was used to guide posttransplant surveillance. All patients underwent evaluation for tumor recurrence at 6-month intervals for the first 24 months and annually thereafter. Tumor surveillance consisted of serum alphafetoprotein (AFP) monitoring and cross-sectional imaging. Additional investigations at 3, 6, 9, and 12 months after transplant were scheduled for stage 3 and 4. Stage 4 tumors were not classified further into a or b because it did not change our overall management of the patient. Overall survival was defined as the interval from the date of the LT to the date of death or most recent follow-up.
Statistical analysis was performed using SPSS software (IBM, Armonk, NY). All means were expressed as mean 6 standard deviation. Comparisons of continuous measures were assessed by the Mann-Whitney U test. Categorical variables were analyzed by the v 2 test. Survival probabilities were estimated using the KaplanMeier method and compared using the log-rank test. Statistical significance was assumed for P < 0.05. Univariate and multivariate analysis was performed using logistic regression, where HCC tumor recurrence was used as an outcome. All analyses used a 5% level of statistical significance. This study was reviewed and approved by the Ochsner institutional review board.
Results
During the study period between June 2005 and December 2014, 1249 LT procedures were performed of which 190 (15.2%) recipients had a pathologic diagnosis of HCC. Fifty-nine (31%) of the grafts were from outside the local OPO and comprised the "ILG" group. The remaining patients all received grafts from within the OPO and were referred to as the LLG group. A total of 54 grafts were imported from region 3 (our local region), and 5 grafts were imported from outside the region (national offers). The reasons these grafts were turned down by the local centers included either presumed risk factor for parenchymal injury (steatosis, DCD, hepatitis B core antibody [HBcAb]1, hepatitis C virus [HCV]) and/or increased risk of donor disease transmission (public health service [PHS] high risk). The age, medical MELD, and gender balance between the ILG and LLG recipients were not statistically significant. Surprisingly, although these grafts were considered discards from other OPOs, the DRI profiles and percentage of graft steatosis between the 2 groups were comparable ( Table 1) . The CIT for ILG was 5.1 hours versus 4.1 hours for the LLG (P < 0.001). Although, the CIT difference was statistically significant, the mean value for ILG is still well below the optimal range of <8 hours for LT. (14) HCV was the etiology of underlying liver disease in the majority of the patients transplanted for HCC and was equally distributed between the groups. There was no selection bias for the use of ILG based on the tumor burden or time spent on the waiting list. Time from listing to transplant was similar for the 2 groups.
SHORT-TERM CLINICAL OUTCOMES
Most HCC recipients were admitted from home for LT and had a low calculated MELD score at the time of transplant. The median length of hospital stay was short and comparable between the 2 groups ( Table 2 ). There were no cases of primary nonfunction in either group. The incidence of acute kidney injury was not increased with the use of ILG. There were no cases of early HAT in either group. One patient in the LLG group developed a late HAT and was treated successfully by conservative measures. The incidence of hepatic artery stenosis was significantly higher in the ILG group as compared with the LLG group (8% versus 1.4%; P 5 0.02). This may be explained by the aggressive use of postoperative ultrasound Doppler surveillance for the presumed higher-risk grafts (eg, DCD grafts). All of these complications were successfully treated using angioplasty or endovascular stents in collaboration with our vascular colleagues. There was 1 graft loss from biliary sepsis secondary to hepatic artery stenosis. The incidence of bile leak and anastomotic biliary stricture rate were comparable between the groups (Table 2) .
OVERALL AND RECURRENCE-FREE SURVIVAL
Complete follow-up data for all patients were available for survival analysis. The overall 1-, 3-, and 5-year patient survival for LLG was 90%, 85%, and 83% versus 85%, 80%, and 79% for the ILG group (P 5 0.08). At a median follow-up of 45 months (range, 10-121 months), there were 18 deaths in the LLG group. In comparison, there were 12 deaths in the ILG at a median follow-up of 31 months (range, 11-94 months). Causes of death for both cohorts included tumor recurrence (n 5 20), ischemic heart disease (n 5 3), infectious complications (n 5 2), graft-versushost disease (n 5 1), late biliary complications (n 5 1), and unknown (n 5 2). The 1-, 3-, and 5-year graft survival for LLG and ILG was 90%, 83%, and 81% versus 85%, 80%, and 78%, respectively. The Kaplan-Meier log-rank test for overall and disease-free survival showed no significant difference between the 2 groups (P 5 0.1).
The observed disease recurrence rate was 11% for LLG recipients and 8% for ILG recipients (P 5 0.1). The median time to recurrence was 7.5 months (range, 4.9-46.9 months) versus 7 months (range, 4.7-21.5 months; P 5 0.3) for the ILG versus LLG, respectively. Univariate and multivariate logistic regression analysis highlighted the well-described tumor-related factors (ie, lymphovascular invasion and degree of differentiation, within Milan was actually shown not to be a significant predictor of recurrence in our data set) as the predictors of HCC recurrence following LT (Table 3) . The use of ILG had no impact on disease-free survival.
Discussion
Although the selection policies are adjusted to maintain equity in access to deceased donor livers for recipients, the problem with wastage of recovered donor organs unfortunately persists. UNOS data suggest 10% of the deceased liver grafts are discarded annually. (15) Over the last decade, the number of consenting donors increased, largely from the cumulative recruitment of elderly donors, DCD donors, donors with positive viral serologies, and donors with "high-risk behaviors." (16, 17) Organs recovered from such donors are commonly labeled as ECD allografts. Despite multiple consensus conferences detailing their use, ECD livers are frequently discarded unless accepted by a center with experience and expertise in their use.
In this study, we report the use of ILGs for patients with HCC, which is largely a surrogate for ECD grafts with longer CIT. The use of ECD organs over the last 5 years at our center has resulted in a dramatic increase NOTE: Data are given as median (range) and n (%). in the number of LTs performed with clinical outcomes comparable to the expected national standards. The 1-year survival for patients was 96.5%, 92.5%, and 91.3% for local, regional, and national liver offers, respectively, at our center based on the latest Scientific Registry of Transplant Recipients (SRTR) data. Similarly, graft survival was noted to be 95.1%, 91.6%, and 90.1% for local, regional, and national liver offers, respectively. These data excluded livers obtained through regional sharing (MELD 35). The median MELD of non-HCC transplant patients during this time period was 17. In addition, the 2015 SRTR showed a 4.5-time increase in the LT rate at our center compared with the nation. HCC was the underlying pathology in >31% of patients (compared with 13.2% and 10.7% regionally and nationally, respectively). At our center between 2010 and 2015, median wait time to LT for all indications was 2.1 months. The LT wait-list dropout rate for this study cohort was 9%.
The acceptance of ILG is based on a thorough assessment of donor clinical history, use of photographs, and microscopic tissue assessment both by the transplant surgeon and an expert liver pathologist. Regardless of the OPO of origin, ECD organs are typically matched to low clinical MELD recipients with no added surgical risk factors to minimize the cold and warm ischemia times.
In general, patients listed from LT with HCC have favorable characteristics for ILG. This ideal candidacy has been challenged by a presumed increase in the risk of HCC recurrence due to short wait times and preferred lack of biological selection. ECD organs are thought to be at an increased risk for enhanced IRI, and murine models have demonstrated that IRI exacerbates tumor cell growth and metastasis by triggering cell adhesion, invasion, and angiogenesis pathways. (7) However, these experimental models were performed in rodents in a nontransplant setting, and there is no robust clinical evidence to support the theory. Two recently published studies investigated the impact of IRI on tumor recurrence in HCC recipients receiving DCD grafts. (18, 19) Both studies concluded that the type of liver graft has no impact on tumor recurrence after LT. The data originated from 2 large centers with different clinical practice guidelines. In the United Kingdom, liver allocation for HCC is based on wait times, and it is a common practice to consider low MELD HCC patients as ideal recipients for ECD grafts. The authors realize there are several limitations to this study. This was a retrospective review and was not a prospective study. In addition, the study size was small and would only be able to detect larger differences in outcomes between the 2 groups of patients. More subtle differences between the 2 groups would only be detectable with a much larger sample size. Finally, our usage of ILGs increased dramatically in the last 5 years, and we will continue to follow these groups to understand the longterm survival trends. It is possible with longer follow-up of the more recent group of patients that late recurrences could occur and these are not reflected in the current reported survival curves. There were also medical risk factor-related deaths in the ILG cohort that were not noticed in the LLG group. On the basis of this experience, we implemented a medical risk score along with a surgical risk assessment. This will potentially help direct the ILG to recipients with a lower medical and surgical risk for possible better patient and graft survival.
In conclusion, deceased donor liver grafts are a precious and scarce resource and every effort should be made to critically assess these organs prior to discarding. Acceptable outcomes using ECD grafts can be achieved by experienced LT teams with careful assessment of each liver graft and minimization of modifiable risk factors such as CITs. When appropriately matched to low-risk recipients, imported grafts can result in comparable outcomes and no increased risk of HCC recurrence.
